Kim Sung-Min, Yang Naery Euphrasia, Jeong Dajeong, Yun Jiwon, Ryu Sohee, Yoon Sung-Soo, Ahn Yong-Oon, Lee Dong Soon
Cancer Research Institute Seoul National University College of Medicine Seoul South Korea.
Department of Laboratory Medicine Sejong General Hospital Bucheon Republic of Korea.
EJHaem. 2020 Sep 22;1(2):563-566. doi: 10.1002/jha2.103. eCollection 2020 Nov.
Next-generation flow (NGF) has detected minimal residual disease (MRD) in numerous myeloma patients who achieve a complete response (CR). However, when MRD is not detected via NGF in non-CR patients, its clinical meaning is uncertain. Here, we investigated the correlation between MRD findings on NGF and the response criteria, paying special attention to patients with discrepant results. We performed NGS analysis of IgH rearrangements on bone marrow samples from the non-CR patients with negative MRD on NGF. NGS detected residual abnormal clones in those patients, suggesting that NGF and NGS should be used in a complementary manner for MRD investigation.
新一代流式细胞术（NGF）已在众多达到完全缓解（CR）的骨髓瘤患者中检测到微小残留病（MRD）。然而，在未达到CR的患者中，若通过NGF未检测到MRD，其临床意义尚不确定。在此，我们研究了NGF检测的MRD结果与缓解标准之间的相关性，特别关注结果不一致的患者。我们对NGF检测MRD呈阴性的未达到CR患者的骨髓样本进行了IgH重排的二代测序（NGS）分析。NGS在这些患者中检测到残留的异常克隆，提示在MRD检测中应将NGF和NGS互补使用。
